Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

Current cancer immunotherapies are primarily predicated on αβ T cells, with a stringent
dependence on MHC-mediated presentation of tumour-enriched peptides or unique …

Background Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-
SCT) consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute …

Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable
activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure …

Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and
transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell …

Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …

Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …

Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell
death that activates, rather than suppresses, innate and adaptive immune responses. Such …

Background The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic
leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric …

CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy
providing excellent remission rates and durable disease control for patients with …